English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Expression of the adenosine triphosphate‐binding cassette B1 (  ABCB 1 ) transporter and P‐glycoprotein are associated with resistance to anticancer drugs. The purpose of this study was to investigate the role of single nucleotide polymorphism in the   ABCB 1  and  CYP 3A genes in breast cancer patients who were treated with neoadjuvant chemotherapy. Stage  II / III  breast cancer patients were treated with three cycles of neoadjuvant, after which the patients received curative surgery and adjuvant chemotherapy. The polymorphisms of  ABCB 1 and  CYP 3A were genotyped. The correlation of polymorphism of   ABCB 1 ,  CYP 3A, and clinical outcomes was analyzed. Among the 216 patients,   ABCB 1 3435  TT  genotype had a longer overall survival (OS). than CC/CT. Multivariate analyses demonstrated that good  PS , invasive ductal carcinoma, non‐triple negative phenotype and initial operable stage were significantly associated with a lower death risk.   ABCB 1 3435  TT  genotype had a higher  AUC  than  CC / CT  for docetaxel. These higher  AUC s in the C3435 TT  was associated with increased toxicities of neutropenia and diarrhea. This study showed that the genetic polymorphism of   ABCB 1  C3435T might be associated with a longer  OS . Our results also suggest that the prediction of docetaxel toxicity might be possible for C3435T polymorphism. This study results provides valuable information on individualized therapy according to genotypes.

ABCB 1 polymorphism as prognostic factor in breast cancer patients treated with docetaxel and doxorubicin neoadjuvant chemotherapy